Related references
Note: Only part of the references are listed.2021 clinical trials update: Innovations in hemophilia therapy
Stacy E. Croteau et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes
Ampaiwan Chuansumrit et al.
HAEMOPHILIA (2021)
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures
Isabella McCary et al.
HAEMOPHILIA (2020)
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
Benjamin J. Samelson-Jones et al.
FRONTIERS IN IMMUNOLOGY (2020)
BioMarin Defends Up-to-$3M List Price of Hemophilia A Gene Therapy
Alex Philippidis
HUMAN GENE THERAPY (2020)
A Real-World Analysis of Commonly Prescribed FVIII Products Based on US Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients
Songkai Yan et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2020)
Regional variation and cost implications of prescribed extended half-life factor concentrates among US Haemophilia Treatment Centres for patients with moderate and severe haemophilia
Stacy E. Croteau et al.
HAEMOPHILIA (2019)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
Johannes Oldenburg et al.
HAEMOPHILIA (2019)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gene therapy in hemophilia A: a cost-effectiveness analysis
Nicoletta Machin et al.
BLOOD ADVANCES (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Novel approaches to hemophilia therapy: successes and challenges
Valder R. Arruda et al.
BLOOD (2017)
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008
S. Guh et al.
HAEMOPHILIA (2012)
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008
S. Guh et al.
HAEMOPHILIA (2012)
Share Paper
